uniQure (NASDAQ:QURE) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of uniQure (NASDAQ:QURE) from a hold rating to a sell rating in a report published on Saturday.

A number of other research firms have also commented on QURE. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Mizuho raised their target price on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Chardan Capital lifted their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, HC Wainwright boosted their target price on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.00.

uniQure Stock Up 3.4%

Shares of QURE stock opened at $43.63 on Friday. The stock’s 50 day simple moving average is $37.49 and its 200 day simple moving average is $26.25. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.40 and a current ratio of 10.01. uniQure has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -10.88 and a beta of 0.90.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter last year, the firm posted ($0.69) earnings per share. As a group, research analysts predict that uniQure will post -3.74 EPS for the current year.

Insider Activity

In other news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider directly owned 169,669 shares in the company, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 164,429 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total value of $7,287,493.28. Following the completion of the transaction, the chief executive officer owned 558,810 shares of the company’s stock, valued at $24,766,459.20. The trade was a 22.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 433,229 shares of company stock valued at $17,944,799. Corporate insiders own 4.65% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp lifted its holdings in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. increased its stake in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC raised its position in uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC raised its position in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares in the last quarter. Finally, MPM Bioimpact LLC bought a new position in uniQure during the fourth quarter worth about $33,062,000. Institutional investors own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Barclays maintained its Buy rating on uniQure, supporting the bullish case for the stock. HC Wainwright also kept a Buy rating and an $80 price target, well above recent trading levels. Barclays Keeps Their Buy Rating on uniQure
• Positive Sentiment: HC Wainwright’s forecasts still anticipate a transition to profitability, projecting positive EPS of $1.95 in fiscal 2029 and $5.07 in fiscal 2030. That long-term earnings potential may help support investor interest despite near-term losses.
• Neutral Sentiment: The FDA’s possible advisory committee meeting for AMT-130 could provide greater clarity on the Huntington’s disease therapy’s regulatory path. However, the timing and outcome remain uncertain, limiting the immediate investment takeaway. uniQure welcomes possible advisory committee for Huntington’s asset
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030. The firm now expects losses of $3.98 per share in 2026 and $3.87 in 2027, while lowering its 2028 estimate to a $1.07 loss and cutting projected 2029 and 2030 profits. These revisions suggest a slower or more costly path to profitability.
• Negative Sentiment: Wall Street Zen downgraded uniQure to Sell, adding a bearish signal alongside concerns about regulatory uncertainty surrounding AMT-130. uniQure downgraded to Sell by Wall Street Zen

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.